Seattle Genetics Reports Third Quarter 2015 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- Strong AI earnings lift S&P 500, Nasdaq as inflation data calms rate-hike jitters
- Oil prices little changed as investors weigh lower demand against US-Iran talks deadlock
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
- After-Hours Movers: SPCX, AMD, ANET, PINS, APPS, UPST, ZETA, BKNG, LCID, CPNG, MTCH
Seattle Genetics (SGEN) Recorded Record Sales Following Label Expansion; Needham & Company Reiterates Buy
October 30, 2015 1:12 PM EDTNeedham & Company reiterated a Buy rating and $60.00 price target on Seattle Genetics (NASDAQ: SGEN) fallowing the company's 3Q earnings results. Adcetris reported record quarterly sales of $59 million, following the company's label expansion into post transplant Hodgkin's lymphoma (HL).
Analyst Chad Messer commented, "Following... More
Piper Jaffray Upgrades Seattle Genetics (SGEN) to Neutral
October 30, 2015 7:06 AM EDTPiper Jaffray upgraded Seattle Genetics (NASDAQ: SGEN) from Underweight to Neutral with a price target of $44.00 (from $30.00).
Analyst Edward Tenthoff commented, "GEN reported ADCETRIS sales of $59 million in 3Q:15 and management again raised 2015 ADCETRIS sales guidance to $218-223 million, and our... More
Seattle Genetics (SGEN) Misses Q3 EPS by 1c
October 29, 2015 4:17 PM EDTSeattle Genetics (NASDAQ: SGEN) reported Q3 EPS of ($0.21), $0.01 worse than the analyst estimate of ($0.20). Revenue for the quarter came in at $84.1 million versus the consensus estimate of $82.67 million.
ADCETRIS sales in the third quarter of $59.1 million, an increase from $48.2 million in the third... More
